Central nervous system tumours are the most common solid tumours and the leading cause of cancer mortality in children, with high biological and prognostic heterogeneity. Despite advances in the 2021 WHO molecular classifications, treatment options remain limited and often ineffective in high-grade tumours. New third-generation sequencing technologies and three-dimensional models derived from patient tumours offer promising tools for more comprehensive genomic characterisation and preclinical evaluation of drug responses. However, the lack of integrated preclinical studies remains a limitation, necessitating coordinated projects to develop personalised therapeutic strategies. The study aims to investigate the genetic and biological characteristics of paediatric brain tumours. To this end, tumour tissue samples taken during planned surgery and peripheral blood samples will be analysed. Advanced genetic analyses will be performed on these materials to identify tumour alterations and the patient's genetic characteristics. In addition, experimental in vitro models derived from the tumour will be developed to evaluate the response to different chemotherapy drugs. The information obtained will be used to better understand the mechanisms of tumour growth and resistance and to promote the future development of more targeted and personalised therapies.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
50
Analysis of genomic DNA from tumor biopsy and blood samples
Meyer Children's Hospital IRCCS
Florence, Firenze, Italy
RECRUITINGNumber of Single Nucleotide Variants (SNV)
Number of SNVs germline in DNA from tumor and blood samples
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Number of copy number variations (CNVs)
Number of copy number variations (CNVs) in DNA from tumor and blood samples
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Number of triplet expansions
Number of triplet expansions in DNA from tumor and blood samples
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Number of structural variants (SVs)
Number of structural variants (SVs) in DNA from tumor and blood sample
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Morphological description of three-dimensional models derived from the tumour
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Vitality of three-dimensional models derived from the tumour
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Proliferative activity of three-dimensional models derived from the tumour
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Percentage of residual cell vitality after drug treatment
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
Dose-response curves for each drug tested
Ex vivo chemosensitivity study on three-dimensional models derived from primary tumour cells
Time frame: At enrollment and on the date of first documented progression assessed up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.